Legend Biotech CEO reports initial share holdings

Legend Biotech Corp Chief Executive Officer Huang Ying filed an initial ownership report showing direct holdings of 257,374 Ordinary Shares.

Rhea-AI Filing Summary

Legend Biotech Corp Chief Executive Officer Huang Ying filed an initial ownership report showing direct holdings of 257,374 Ordinary Shares. This total includes 43,010 restricted share units, with 28,119 shares scheduled to vest on March 20, 2026 and 14,891 on June 20, 2026, subject to continued service.

Huang also reports multiple share options over Ordinary Shares at exercise prices from $1.5000 to $27.5000, expiring between July 21, 2029 and April 2, 2033. Footnotes state that some options are immediately exercisable, while others vest on April 3, 2026. Each American Depositary Share represents two Ordinary Shares.

Insider Trade Summary

9 transactions reported

Mixed 9 txns

Insider Huang Ying

Role Chief Executive Officer

Type	Security	Shares	Price	Value
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Share Option (right to buy) — 580,372 contracts (Direct); Ordinary Shares — 257,374 shares (Direct)

Footnotes (5)

1. F1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
2. F2. Includes 43,010 restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 28,119 shares underlying the RSU will vest on March 20, 2026 and the remaining 14,891 shares will vest on June 20, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
3. F3. All of the shares subject to the option are immediately exercisable.
4. F4. All of the shares subject to the option shall vest on April 3, 2026.
5. F5. 40,000 of the shares subject to the option are immediately exercisable and the remainder shall vest on April 3, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Huang Ying report owning in Legend Biotech (LEGN) on this Form 3?

Huang Ying reports direct ownership of 257,374 Ordinary Shares of Legend Biotech. This amount includes 43,010 restricted share units that convert into ordinary shares upon vesting, plus several option grants over additional Ordinary Shares at specified exercise prices and expirations.

How many restricted share units does the Legend Biotech CEO hold and when do they vest?

The CEO holds 43,010 restricted share units. According to the disclosure, 28,119 shares are scheduled to vest on March 20, 2026, with the remaining 14,891 shares vesting on June 20, 2026, contingent on continued service to Legend Biotech.

What stock options are reported by the Legend Biotech CEO on this Form 3?

Huang Ying reports multiple share options over Ordinary Shares. Examples include options over 121,746 shares at an exercise price of $1.5000 expiring on July 21, 2029, and 185,340 shares at $27.5000 expiring on June 29, 2032.

Are any of the Legend Biotech CEO’s options immediately exercisable?

Yes. A footnote states that all shares subject to one option grant are immediately exercisable. Another grant provides that 40,000 shares are immediately exercisable, with the remaining option shares vesting on April 3, 2026, subject to continued service.

How are Legend Biotech Ordinary Shares represented by American Depositary Shares (ADSs)?

The disclosure explains that Legend Biotech’s Ordinary Shares may be represented by American Depositary Shares. Each ADS represents two Ordinary Shares, providing a direct ratio for investors who hold ADSs instead of the underlying Ordinary Shares.

Does this Legend Biotech Form 3 show any insider buying or selling activity?

No specific buy or sell transactions are reported. The Form 3 presents Huang Ying’s existing holdings in Ordinary Shares, restricted share units, and share options as of the reporting date, rather than documenting new purchases or sales in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 06:50 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Huang Ying

(Last) (First) (Middle)

C/O LEGEND BIOTECH CORP

2101 COTTONTAIL LANE

(Street)

SOMERSET NEW JERSEY 08873

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Legend Biotech Corp [ LEGN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	257,374(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	(3)	07/21/2029	Ordinary Shares	81,788	$1.5	D
Share Option (right to buy)	(3)	06/29/2032	Ordinary Shares	3,636	$27.5	D
Share Option (right to buy)	(4)	04/02/2033	Ordinary Shares	4,248	$23.53	D
Share Option (right to buy)	(3)	07/21/2029	Ordinary Shares	35,728	$1.5	D
Share Option (right to buy)	(3)	07/21/2029	Ordinary Shares	121,746	$1.5	D
Share Option (right to buy)	(3)	03/25/2031	Ordinary Shares	92,134	$14.12	D
Share Option (right to buy)	(3)	06/29/2032	Ordinary Shares	185,340	$27.5	D
Share Option (right to buy)	(5)	04/02/2033	Ordinary Shares	55,752	$23.53	D

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.

2. Includes 43,010 restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 28,119 shares underlying the RSU will vest on March 20, 2026 and the remaining 14,891 shares will vest on June 20, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

3. All of the shares subject to the option are immediately exercisable.

4. All of the shares subject to the option shall vest on April 3, 2026.

5. 40,000 of the shares subject to the option are immediately exercisable and the remainder shall vest on April 3, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ James Pepin, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)